Olmesartan Medoxomil
Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: No human data; use with caution
Hypertension, Diabetic nephropathy,
Pregnancy (2nd and 3rd trimesters); biliary obstruction.
N/A
1-10% Dizziness,Headache,Fatigue,Diarrhea,Hyperglycemia,Hypertriglyceridemia,Back pain,Bronchitis,Inflicted injury,Flulike symptoms,Pharyngitis,Rhinitis,Sinusitis,Upper respiratory tract infection (URTI) Frequency Not Defined (selected) Anaphylactic reaction,Angioedema,Facial edema,Rhabdomyolysis,Hyperkalemia,Tachycardia,Hypercholesterolemia,Gastroenteritis,Hyperlipidemia Potentially Fatal: Acute renal failure.
Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.
Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Oral Hypertension Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed. Elderly: No dosage adjustment needed. Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.
Oral Hypertension Child: 6-16 yr <35 kg: 10 mg once daily; dosage range: 10-20 mg/day >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk. dosage range: 20-40 mg/day
Renal impairment: Mild to moderate (CrCl: 20-60 mL/min): Max: 20 mg once daily.
N/A
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.